Christopher Boerner

Christopher Boerner

Chief Executive Officer at BRISTOL-MYERS SQUIBB COMPANY

Net worth: 9 M $ as of 2026-02-27

55 year
Health Technology
Consumer Services
Commercial Services

Profile

Dr. Christopher S.
Boerner
is a Chairman & Chief Executive Officer at Bristol Myers Squibb Co. He is on the Board of Directors at Capital Health System, Inc. and Pharmaceutical Research & Manufacturers of America.
Dr. Boerner was previously employed as an Independent Director by Achaogen, Inc., an Executive Vice President-Commercial by Seattle Genetics, Inc., a Vice President-Marketing by Dendreon Corp., a Marketing Director by Genentech, Inc., and an Associate by McKinsey & Co., Inc. He received his undergraduate degree from Washington University in St. Louis, a graduate degree from Haas School of Business and a doctorate degree from Haas School of Business.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-03-09 146,890 ( 0.01% ) 9 M $ 2026-02-27

Christopher Boerner active positions

CompaniesPositionStart
BRISTOL-MYERS SQUIBB COMPANY Chief Executive Officer 2023-10-31
Director/Board Member -
Director/Board Member -

Former positions of Christopher Boerner

CompaniesPositionEnd
ACHAOGEN Director/Board Member 2015-06-09
SEAGEN INC. Corporate Officer/Principal 2015-01-29
DENDREON CORPORATION Sales & Marketing -
Sales & Marketing 2009-12-31
Corporate Officer/Principal -
See the detail of Christopher Boerner's experience

Training of Christopher Boerner

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

71

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Commercial Services

Health Services

Health Technology

Consumer Services

  1. Stock Market
  2. Insiders
  3. Christopher Boerner
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW